Current Report Filing (8-k)
June 17 2020 - 9:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 17, 2020
GENEREX
BIOTECHNOLOGY CORPORATION
(Exact
of registrant as specified in its charter)
DELAWARE
|
000-29169
|
98-0178636
|
State
or other jurisdiction of incorporation
|
Commission
File Number
|
IRS
Employer Identification No.
|
10102
USA Today Way, Miramar, Florida 33025
(Address of principal executive offices) (Zip Code)
(416)
364-2551
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
N/A
|
N/A
|
N/A
|
Item
8.01 Other Events.
On
April 24, 2020, Generex Biotechnology Corporation (“Generex”) received a letter of support from UC San Diego
School of Medicine regarding Generex’s efforts to develop Generex’s li-Key-SARS-CoV-2 peptide vaccine with the goal
to begin mass vaccination in the Fall of 2020. A copy of the letter of support is attached to this report as Exhibit 99.1 and
is incorporated by reference herein.
UC
San Diego School of Medicine, established in 1968, is the region’s only medical school. As a top-tier academic medical center,
its role is to improve health through innovative research, education and patient care. The School of Medicine is closely tied
to the Skaggs School of Pharmacy and Pharmaceutical Sciences and UC San Diego Health, which includes the UC San Diego Medical
Center, Jacobs Medical Center, Moores Cancer Center, Sulpizio Cardiovascular Center, Shiley Eye Institute and many other centers,
clinics and affiliates throughout Southern California.
Forward-Looking
Statements
Statements
in this report may contain certain forward-looking statements. All statements included concerning activities, events or developments
that the Generex expects, believes or anticipates will or may occur in the future are forward-looking statements. Actual results
could differ materially from the results discussed in the forward-looking statements. Forward-looking statements are based on
current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors
that may cause actual results and performance to be materially different from any future results or performance expressed or implied
by forward-looking statements. Known risks and uncertainties also include those identified from time to time in the reports filed
by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future
events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical
trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical
trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval
for any “phase” of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory
agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities
Litigation Reform Act. Additional information on these and other risks, uncertainties and factors is included in the Company’s
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8- K and other documents filed with the SEC.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
|
Description
|
99.1
|
Letter of Support provided by UC San Diego School of Medicine dated April 24, 2020
|
U.S. Department of Health and Human Services
200 Independence Avenue SW
Washington, DC 20201
Office of the Assistant Secretary
for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA):
It is our understanding
that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop the Ii-Key-SARS-CoV-2
peptide vaccine with the goal to begin vaccination in the Fall of 2020. This will require the collection of convalescent plasma
for the screening and selection of peptides to be included in the final vaccine formulation. This formulation will then be
administered as part of an adaptive design protocol in a clinical trial to assess safety and immunogenicity. Concurrently,
a similar clinical trial will be conducted in a special population of healthcare workers. Subsequent special population trials
will be conducted in pediatric, geriatric, and immunocompromised populations.
Please accept this letter as notice of our intent
to support Generex Biotechnology and BARDA’s efforts to develop the Ii-Key-SARS-CoV-2/COVID-19 vaccine. Although we
cannot commit financial support or inkind services at this time, we are eager to provide clinical and laboratory expertise.
As resources permit, we are willing to assist in providing convalescent plasma and providing laboratory analysis for vaccine
formulation and evaluation of efficacy endpoints for the clinical trials. We recognize the urgent need for vaccine development
and are committed to partnering with Generex Biotechnology and BARDA to make it a reality.
Sincerely,
Davey Smith, MD, MAS
Chief | Division of Infectious Diseases and Global
Public Health
Professor and Vice Chair of Faculty | Department of Medicine
Co-Director | San Diego California for AIDS Research (CFAR)
University of California San Diego
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
June 17, 2020
GENEREX
BIOTECHNOLOGY CORPORATION
/s/Joseph
Moscato
By:
Joseph Moscato, CEO, President
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2023 to Apr 2024